Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    uPAR
Show Display Options
Rank Status Study
1 Recruiting uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
Condition: Urinary Bladder Neoplasms
Interventions: Drug: Injection of 68Ga-NOTA-AE105;   Drug: Injection of 18F-FDG;   Device: Positron Emission Tomography and CT;   Device: Positron Emission Tomography and MRI
2 Recruiting uPAR PET/CT for Preoperative Staging of Breast Cancer Patients
Condition: Breast Cancer
Interventions: Other: 68Ga-NOTA-AE105;   Device: Positron Emission Tomography PET/CT
3 Terminated Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Abiraterone;   Drug: Prednisolone
4 Completed Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
Conditions: Breast Cancer;   Prostate Cancer;   Urinary Bladder Cancer
Interventions: Drug: Injection of 68Ga-NOTA-AE105;   Device: Positron Emission Tomography scans
5 Completed Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
Conditions: Breast Cancer;   Prostate Cancer;   Urinary Bladder Cancer
Intervention: Other: Injection of 64Cu-DOTA-AE105
6 Recruiting uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Conditions: Non-small Cell Lung Cancer;   Malignant Pleural Mesothelioma;   Large Cell Neuroendocrine Carcinoma of the Lung
Intervention: Other: 68Ga-NOTA-AE105 PET/CT
7 Completed Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
Condition: BPH
Intervention: Procedure: transurethral resection of the prostate
8 Unknown  Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis
Condition: Neonatal Sepsis
9 Completed Dietary Seaweed and Early Breast Cancer: A Randomized Trial
Condition: Seaweed Associated Changes in Healthy Subjects
Interventions: Other: Seaweed;   Other: Placebo;   Other: Placebo2
10 Unknown  GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy
Condition: Prostate Cancer
Interventions: Other: Low Dose GTN 0.0285 mg/hr;   Other: High Dose GTN 0.057 mg/hr;   Other: Placebo
11 Recruiting suPAR in the Early Diagnosis of Acute Kidney Injury(AKI) After On-Pump Cardiac Surgery
Condition: Acute Kidney Injury
12 Unknown  Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma
Conditions: Breast Neoplasms;   Mastectomy
Intervention: Drug: Solu-medrol 125 mg
13 Recruiting A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
Condition: FSGS
14 Active, not recruiting Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Conditions: Prostate Cancer;   Elevated Prostate Specific Antigen (PSA)
Intervention: Other: serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
15 Recruiting A Crossover Pilot Study of the Effect of Amiloride on Proteinuria
Condition: Proteinuria
Interventions: Drug: Amiloride;   Drug: Triamterene
16 Recruiting Healing Hearts and Mending Minds in Older Adults Living With HIV
Conditions: HIV;   Cardiovascular Disease;   AIDS
Interventions: Behavioral: Let's Move Program;   Behavioral: Let's Flex Program;   Behavioral: Group Motivational Interviewing
17 Recruiting Role of SLURP-1 in Melanoma and Melanoma Stem Cells
Condition: Melanoma;
18 Recruiting Clinical Evaluation of Novel Biomarkers in Patients With Septicemia
Conditions: Sepsis;   Bacteremia;   Fungemia

Indicates status has not been verified in more than two years